Expression, tumor immune infiltration, and prognostic impact of HMGs in gastric cancer

Background In the past decade, considerable research efforts on gastric cancer (GC) have been expended, however, little advancement has been made owing to the lack of effective biomarkers and treatment options. Herein, we aimed to examine the levels of expression, mutations, and clinical relevance of HMGs in GC to provide sufficient scientific evidence for clinical decision-making and risk management. Methods GC samples were obtained from The Cancer Genome Atlas (TCGA). University of California Santa Cruz (UCSC) XENA, Human Protein Atlas (HPA), Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier Plotter, cBioPortal, GeneMANIA, STRING, LinkedOmics, and DAVID databases were employed. The “ggplot2” package in the R software (×64 3.6.3) was used to thoroughly analyze the effects of HMGs. qRT-PCR was performed to assess HMG levels in GC cell lines. Results A total of 375 GC tissues and 32 paraneoplastic tissues were analyzed. The levels of HMGA1, HMGA2, HMGB1, HMGB2, HMGB3, HMGN1, HMGN2, and HMGN4 expression were increased in GC tissues relative to normal gastric tissues. HMGA1, HMGA2, HMGB1, HMGB2, and HMGB3 were highly expressed in GC cell lines. The OS was significantly different in the group showing low expressions of HMGA1, HMGA2, HMGB1, HMGB2, HMGB3, HMGN2, HMGN3, and HMGN5. There was a significant difference in RFS between the groups with low HMGA2, HMGB3, and high HMGN2 expression. The levels of HMGA2, HMGB3, and HMGN1 had a higher accuracy for prediction to distinguish GC from normal tissues (AUC value > 0.9). HMGs were tightly associated with immune infiltration and tumor immune escape and antitumor immunity most likely participates in HMG-mediated oncogenesis in GC. GO and KEGG enrichment analyses showed that HMGs played a vital role in the cell cycle pathway. Conclusions Our results strongly suggest a vital role of HMGs in GC. HMGA2 and HMGB3 could be potential markers for prognostic prediction and treatment targets for GC by interrupting the cell cycle pathway. Our findings might provide renewed perspectives for the selection of prognostic biomarkers among HMGs in GC and may contribute to the determination of the optimal strategy for the treatment of these patients.

[1]  Jing Chen,et al.  HMGN4 plays a key role in STAT3-mediate oncogenesis of triple-negative breast cancer. , 2022, Carcinogenesis.

[2]  B. Kong,et al.  HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer , 2022, Cell Death & Disease.

[3]  Shuyi Wang,et al.  The lncRNA SEMA3B-AS1/HMGB1/FBXW7 Axis Mediates the Peritoneal Metastasis of Gastric Cancer by Regulating BGN Protein Ubiquitination , 2022, Oxidative medicine and cellular longevity.

[4]  C. Pereira,et al.  HMGA1 Has Predictive Value in Response to Chemotherapy in Gastric Cancer , 2021, Current Oncology.

[5]  F. Qi,et al.  LINC00857 promotes colorectal cancer progression by sponging miR-150-5p and upregulating HMGB3 (high mobility group box 3) expression , 2021, Bioengineered.

[6]  Zhibin Zhang,et al.  Hsa_circ_0060937 accelerates non-small cell lung cancer progression via modulating miR-195-5p/HMGB3 pathway , 2021, Cell cycle.

[7]  Xiaosheng Wang,et al.  Identification of gastric cancer subtypes based on pathway clustering , 2021, npj Precision Oncology.

[8]  Dong Liu,et al.  Nuclear exosome HMGB3 secreted by nasopharyngeal carcinoma cells promotes tumour metastasis by inducing angiogenesis , 2021, Cell Death & Disease.

[9]  Jun Peng,et al.  MiR-93/HMGB3 regulatory axis exerts tumor suppressive effects in colorectal carcinoma cells. , 2021, Experimental and molecular pathology.

[10]  Hongbo Zhang,et al.  microRNA-130a-5p suppresses myocardial ischemia reperfusion injury by downregulating the HMGB2/NF-κB axis , 2021, BMC Cardiovascular Disorders.

[11]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[12]  K. Zhao,et al.  The role of high mobility group protein B3 (HMGB3) in tumor proliferation and drug resistance , 2021, Molecular and Cellular Biochemistry.

[13]  H. Pass,et al.  HMGB1 as a therapeutic target in disease , 2020, Journal of cellular physiology.

[14]  A. Fusco,et al.  Interplay between HMGA and TP53 in cell cycle control along tumor progression , 2020, Cellular and Molecular Life Sciences.

[15]  H. Grabsch,et al.  Gastric cancer , 2020, The Lancet.

[16]  X. Gu,et al.  LncRNA SNHG5 promotes nasopharyngeal carcinoma progression by regulating miR-1179/HMGB3 axis , 2020, BMC Cancer.

[17]  Jingjing Xie,et al.  Bioinformatics analysis of the prognosis and biological significance of HMGB1, HMGB2, and HMGB3 in gastric cancer , 2019, Journal of cellular physiology.

[18]  L. Cope,et al.  High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer , 2019, Breast Cancer Research and Treatment.

[19]  Jian-Qin Wang,et al.  MicroRNA‐329 upregulation impairs the HMGB2/β‐catenin pathway and regulates cell biological behaviors in melanoma , 2019, Journal of cellular physiology.

[20]  Shujun Gao,et al.  High‐mobility group box 2 promoted proliferation of cervical cancer cells by activating AKT signaling pathway , 2019, Journal of cellular biochemistry.

[21]  Jun Gu,et al.  HMGB3 silence inhibits breast cancer cell proliferation and tumor growth by interacting with hypoxia-inducible factor 1α , 2019, Cancer management and research.

[22]  Ling Gao,et al.  HMGB2 promotes the malignancy of human gastric cancer and indicates poor survival outcome. , 2019, Human pathology.

[23]  Hongwei Wang,et al.  The nucleosome binding protein 1 promotes the growth of gastric cancer cells , 2019, Journal of Cancer.

[24]  K. Matsushima,et al.  Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice , 2019, Journal of Immunotherapy for Cancer.

[25]  Guixia Wu,et al.  Effect of HMGN2 on proliferation and apoptosis of MCF-7 breast cancer cells , 2018, Oncology letters.

[26]  Jianxun Liu,et al.  HMGB3 promotes the proliferation and metastasis of glioblastoma and is negatively regulated by miR‐200b‐3p and miR‐200c‐3p , 2018, Cell biochemistry and function.

[27]  J. Oppenheim,et al.  High-mobility group nucleosome binding domain 1 (HMGN1) functions as a Th1-polarizing alarmin. , 2018, Seminars in immunology.

[28]  L. Resar,et al.  Lessons from the Crypt: HMGA1-Amping up Wnt for Stem Cells and Tumor Progression. , 2018, Cancer research.

[29]  D. Suren,et al.  High Mobility Group Box 1 (HMGB1) expression in gastric adenocarcinomas. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[30]  A. Naiki‐Ito,et al.  Early detection of prostate carcinogens by immunohistochemistry of HMGB2. , 2018, The Journal of toxicological sciences.

[31]  Dangdang Li,et al.  Evidence For Hmgn2 Involvement in Mouse Embryo Implantation and Decidualization , 2017, Cellular Physiology and Biochemistry.

[32]  J. Xiong,et al.  HMGB3 modulates ROS production via activating TLR cascade in Apostichopus japonicus. , 2017, Developmental and comparative immunology.

[33]  Fan Zhang,et al.  HMGB3 promotes growth and migration in colorectal cancer by regulating WNT/β-catenin pathway , 2017, PloS one.

[34]  Yuanyu Wu,et al.  Progress in the treatment of advanced gastric cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[35]  Jing-hua Zhang,et al.  Long non-coding RNA MALAT1 drives gastric cancer progression by regulating HMGB2 modulating the miR-1297 , 2017, Cancer Cell International.

[36]  M. Bustin,et al.  Elevated HMGN4 expression potentiates thyroid tumorigenesis , 2017, Carcinogenesis.

[37]  Mary Goldman,et al.  Toil enables reproducible, open source, big biomedical data analyses , 2017, Nature Biotechnology.

[38]  Shengnan Guo,et al.  Knockdown of High Mobility Group-Box 3 (HMGB3) Expression Inhibits Proliferation, Reduces Migration, and Affects Chemosensitivity in Gastric Cancer Cells , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[39]  Xin Tang,et al.  MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3. , 2016, Biochemical and biophysical research communications.

[40]  Yanhua Cao,et al.  HMGA1 facilitates tumor progression through regulating Wnt/β-catenin pathway in endometrial cancer. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[41]  Lin Zhao,et al.  HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review , 2016, Oncotarget.

[42]  J. Jung,et al.  HMGA1/HMGA2 protein expression and prognostic implications in gastric cancer. , 2015, International journal of surgery.

[43]  Y. Shang,et al.  miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2 , 2015, Cell Death and Disease.

[44]  Chenglin Zhang,et al.  Nucleosome-binding protein HMGN2 exhibits antitumor activity in human SaO2 and U2-OS osteosarcoma cell lines. , 2015, Oncology reports.

[45]  Z. Zou,et al.  Increased expression of HMGB3: a novel independent prognostic marker of worse outcome in patients with esophageal squamous cell carcinoma. , 2015, International journal of clinical and experimental pathology.

[46]  M. Weng,et al.  The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells , 2015, Tumor Biology.

[47]  M. Bustin,et al.  The Alarmin HMGN1 contributes to antitumor immunity and is a potent immunoadjuvant. , 2014, Cancer research.

[48]  Yun Feng,et al.  HMGN2, a new anti-tumor effector molecule of CD8+ T cells , 2014, Molecular Cancer.

[49]  Yubin Kou,et al.  Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo. , 2014, International journal of oncology.

[50]  Xuhui Zhou,et al.  High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy , 2014, Tumor Biology.

[51]  Qianming Chen,et al.  Nucleosome-binding protein HMGN2 exhibits antitumor activity in oral squamous cell carcinoma , 2013, Oncology letters.

[52]  C. Wang,et al.  HMGB3 characterization in gastric cancer. , 2013, Genetics and molecular research : GMR.

[53]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[54]  P. Correa Gastric cancer: overview. , 2013, Gastroenterology clinics of North America.

[55]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[56]  Ya-wei Shi,et al.  High mobility group-box 3 overexpression is associated with poor prognosis of resected gastric adenocarcinoma. , 2012, World journal of gastroenterology.

[57]  T. Deng,et al.  The HMGN family of chromatin-binding proteins: dynamic modulators of epigenetic processes. , 2012, Biochimica et biophysica acta.

[58]  M. Bustin,et al.  High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses , 2012, The Journal of experimental medicine.

[59]  M. Bustin,et al.  Regulation of chromatin structure and function by HMGN proteins. , 2010, Biochimica et biophysica acta.

[60]  G. Manfioletti,et al.  HMGA molecular network: From transcriptional regulation to chromatin remodeling. , 2010, Biochimica et biophysica acta.

[61]  A. Fusco,et al.  HMGA and cancer. , 2010, Biochimica et biophysica acta.

[62]  R. Reeves Nuclear functions of the HMG proteins. , 2010, Biochimica et biophysica acta.

[63]  Yinsheng Wang,et al.  HMG modifications and nuclear function. , 2010, Biochimica et biophysica acta.

[64]  M. Bustin,et al.  The Nucleosome Binding Protein HMGN3 Modulates the Transcription Profile of Pancreatic β Cells and Affects Insulin Secretion , 2009, Molecular and Cellular Biology.

[65]  G. Manfioletti,et al.  Macroscopic differences in HMGA oncoproteins post-translational modifications: C-terminal phosphorylation of HMGA2 affects its DNA binding properties. , 2009, Journal of proteome research.

[66]  Debra L Winkeljohn Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[67]  Yun Feng,et al.  Creation and anti-cancer potency in HeLa cells of a novel chimeric toxin, HMGNCIDIN, composed of HMGN2 a-helical domain and PE38 KDEL domain III. , 2008, Chinese medical journal.

[68]  A. Fusco,et al.  Roles of HMGA proteins in cancer , 2007, Nature Reviews Cancer.

[69]  M. Bustin,et al.  HMG chromosomal proteins in development and disease. , 2007, Trends in cell biology.

[70]  K. Jung,et al.  Functional genomics analysis of low concentration of ethanol in human hepatocellular carcinoma (HepG2) cells. Role of genes involved in transcriptional and translational processes , 2006, International journal of medical sciences.

[71]  Michael Bustin,et al.  Down-Regulation of Nucleosomal Binding Protein HMGN1 Expression during Embryogenesis Modulates Sox9 Expression in Chondrocytes , 2006, Molecular and Cellular Biology.

[72]  M. Bianchi,et al.  HMG proteins: dynamic players in gene regulation and differentiation. , 2005, Current opinion in genetics & development.

[73]  M. Bustin,et al.  Chromosomal protein HMGN1 enhances the acetylation of lysine 14 in histone H3 , 2005, The EMBO journal.

[74]  K. West HMGN proteins play roles in DNA repair and gene expression in mammalian cells. , 2004, Biochemical Society transactions.

[75]  A. Fusco,et al.  Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer , 2004, FEBS letters.

[76]  M. Bustin,et al.  HMGN dynamics and chromatin function. , 2003, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[77]  Michael Bustin,et al.  Chromosomal protein HMGN1 enhances the rate of DNA repair in chromatin , 2003, The EMBO journal.

[78]  Erkki Ruoslahti,et al.  A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[79]  D. Landsman,et al.  HMGN4, a newly discovered nucleosome-binding protein encoded by an intronless gene. , 2001, DNA and cell biology.

[80]  M. Bustin Revised nomenclature for high mobility group (HMG) chromosomal proteins. , 2001, Trends in biochemical sciences.

[81]  M. Beltrame,et al.  Upwardly mobile proteins , 2000, EMBO reports.

[82]  C. Croce,et al.  The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. , 1999, Cancer research.

[83]  Michael Bustin,et al.  Regulation of DNA-Dependent Activities by the Functional Motifs of the High-Mobility-Group Chromosomal Proteins , 1999, Molecular and Cellular Biology.

[84]  A. Poustka,et al.  Isolation of human and mouse HMG2a cDNAs: evidence for an HMG2a-specific 3' untranslated region. , 1997, Gene.

[85]  T. Maniatis,et al.  The high mobility group protein HMG I(Y) is an essential structural component of a virus-inducible enhancer complex. , 1993, Cold Spring Harbor symposia on quantitative biology.

[86]  M. Mukai,et al.  Tumor invasion-inhibiting factor 2: primary structure and inhibitory effect on invasion in vitro and pulmonary metastasis of tumor cells. , 1992, Cancer research.

[87]  T. Maniatis,et al.  The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. , 1992, Cell.

[88]  M. Nissen,et al.  The A.T-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. , 1990, The Journal of biological chemistry.

[89]  S. Laland,et al.  On the presence of two new high mobility group‐like proteins in HeLa S3 cells , 1983, FEBS letters.